

**MTN 017 - Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil
Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Report Generation Date: September 11, 2015
Visit Cutoff Date: August 24, 2015
Summary of Missed Visits by Site**

	Puerto Rico San Juan	USA Pittsburgh	USA Boston	Thailand Chiang Mai	USA San Francisco
Participants Enrolled	7	33	7	30	38
Missed Visits ¹	0/56 (0.0%)	0/264 (0.0%)	1/56 (1.8%)	0/240 (0.0%)	13/304 (4.3%)

	Thailand Bangkok	South Africa Cape Town	Peru Lima	All Sites
Participants Enrolled	24	18	38	195
Missed Visits ¹	0/192 (0.0%)	10/144 (6.9%)	9/304 (3.0%)	33/1560 (2.1%)

¹ Number of missed visits (based on receipt of a Missed Visit CRF) divided by total number of expected follow-up visits whereby the visit window has closed.

**MTN 017 - Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil
 Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel**
Report Generation Date: &Rundate_word
Reporting Period: 01AUG2015 through 31AUG2015
Visit Cutoff Date: &visit_cutdt_word
Summary of Missed Visits by Site

	Puerto Rico San Juan	USA Pittsburgh	USA Boston	Thailand Chiang Mai
Participants Enrolled	7	33	7	30

Participants with a visit window within the reporting period¹

Missed Visits² 0

	USA San Francisco	Thailand Bangkok	South Africa Cape Town	Peru Lima	All Sites
Participants Enrolled	38	24	18	38	195

Participants with a visit window within the reporting period¹ 0

Missed Visits²

¹ Number of participants with at least 1 visit window closed date between 01AUG2015 through 31AUG2015.

² Number of missed visits (based on receipt of a Missed Visit CRF) divided by total number of expected follow-up visits whereby the visit window has closed.